Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NamePW Medtech
Stock Code01358
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於中國醫療器械行業中快速增長及高利潤率分部的醫療器械公司,主要在骨科植入物及高端輸液器分部從事開發、生產及銷售。
Listing Date2013-11-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市朝陽區望京阜通東大街6號方恒國際中心C座505–506室
Business Address (Hong Kong)香港灣仔皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitepwmedtech.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 3.18 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.0001 / shares
Offer Period2013-10-31 to 2013-10-31
Global Offering Shares400,000,000 shares
HK Public Offer Shares (Initial)40,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)360,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,600,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,272,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.52B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +519%

Valuation & Financials

Market Cap (at Offer Price)HK$ 4,784,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣100.2百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-06
Revenue 60,816175,267331,541218,750
Cost of sales -16,629-66,150-112,694-71,360
Gross profit 44,187109,117218,847147,390
Other income and gains, net 308661,570251
Selling and distribution expenses -13,071-23,405-46,821-28,542
Administrative expenses -10,621-17,708-35,603-33,272
Operating profit 19,37261,806128,48179,213
Net finance costs -2,104-4,478-8,760-4,869
Profit before tax 17,26857,328119,72174,344
Income tax expense -2,936-7,982-19,538-14,104
Profit for the year 14,33249,346100,18360,240
Profit attributable to owners 7,11722,10344,66850,014
Balance Sheet
Item 201120122013-06
Cash and cash equivalents 1106,0554,488
Total current assets 1106,0799,394
Total assets 1231,789558,636
Total liabilities 9237,643
Total equity -8231,766550,993
Cash Flow Statement
Item 2010201120122013-06
Net cash from operating activities 11,73515,71324,90631,494
Net cash from investing activities -24,002-246,714-117,581-28,545
Net cash from financing activities 63,336230,001244,030-73,010
Net increase in cash 51,069-1,000151,355-70,061
Purchase of PP&E -19,987-38,039-26,463-1,634
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.51
First Day OpenHK$ 3.18
First Day Change10.38%
First Day Volume165294000.0
First Day Turnover546880000.0
Use of Proceeds
所得款項凈額約50%或559.2百萬港元用于擴展我們的產能及投資于新產品的研發,包括 (i)約25%或279.6百萬港元用于購買生產設備 及完成我們位于北京及山東的新輸液器生產 廠房的建設; (ii)約17%或190.1百萬港元用于拓展我們位于深圳及天津的骨科植入物廠房的產能; (iii)約8%或89.5百萬港元投資于新產品的研發; (2)所得款項凈額約30%或335.5百萬港元用于實 施我們的擴張計劃,包括作出收購及組件策略聯盟; (3)所得款項凈額約10%或111.8百萬港元用于擴展我們的分銷網絡及銷售及營銷團隊,包括聘請專注專業的銷售員工; (4)其余所得款項凈額最高約10%或111.8百萬港元的任何余額用作額外的營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (1)
Morgan Stanley Asia Limited CE AAD291
Joint Bookrunners (1)
Morgan Stanley Asia Limited CE AAD291
Joint Lead Managers (1)
Morgan Stanley Asia Limited CE AAD291

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman林君山—
Company Secretary傅偉霖—
No director data available.

Major Shareholders

Major Shareholders & HoldingsLIU女士及Cross Mark持股34.19%,WP X持股20.45%,陳國泰先生及Right Faith持股14.52%,李毅先生及Sparkle Wealthy持股5.84%。
About this page

This page shows PW Medtech (01358) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect